reason report
pt
bottom line monday host site visit
chanc catch presid ceo bob
presid kevin cordel presid lower extrem
patrick fisher meet posit left site visit
increas confid upward bia estim head
print -- -not recent augment inject
fda approv -- -and achiev above-consensu
low-teen revenue growth project balanc sheet
overhang remov augment inject approv hand
sens lower extrem turnaround materi stock
set-up risk-reward look increasingli compel us
reiter op rate
specif meet highlight four main posit us
lower extrem growth troubl spot throughout
like sustain growth re-acceler trajectori
posit momentum saw segment like carri
continu especi key product launch gain
traction prostep could needle-mov recent rep hire come
product curv better job penetr
ambulatori surgeri center augment inject
potenti import growth acceler driver biolog
franchis beyond sign slow momentum
upper-extrem franchis look capabl sustain mid-teen
growth even long-term commit deliv
ebitda margin improv time sustain dd top-
line growth profil management sight set achiev ebitda
time
pt increas vs prior feel comfort
appli higher vs prior multipl revenue
forecast given last week augment inject approv
think lead upward consensu estim revis posit
discuss senior leadership team follow
increas confid achiev above-consensu out-year
forecast reflect low-teen revenue growth think
multipl still room play addt catch-up rest small-
cap med-tech experienc multipl expans sinc last
nxtm trade
ev/sal average revenue growth prospect perhap slight
discount still warrant given high leverag ratio debt/
ebitda view low-teen top-lin growth prospect
gm profil fetch closer an-lin peer group ev/sal
multipl vs current discount vs especi
compani inform leerink partner llc research
rev/ep continu oper ex-larg joint move disc op ep ex-amort item
medic suppli devic
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
consid end-mkt among best
med-tech let alon ortho grow hsd think
least revenue grower exit acceler potenti
toward low-teen
op-rat ultim believ continu take step help
sustain compani posit market leader fast-growth extrem segment
moreov wmgi/trnx combin view creat attract uniqu mid-cap
growth extremities/biolog asset broad reach across three fastest-grow ortho
market shoulder foot ankl biolog believ stock move higher
investor new exist re-focu health trnx still-rapidli grow
end-market enhanc posit within especi augment inject
approv use select foot ankl procedur sustain long-term double-digit
revenu growth margin expans prospect upsid potenti estim
recent host investor meet manag corpor headquart
memphi tn opportun conduct presid ceo bob
palmisano cfo svp lanc berri svp juli dewey presid kevin cordel
presid lower extrem patrick fisher meet posit view
left site visit increas confid upward bia estim head
print -- -not recent augment inject fda approv -- -and
achiev above-consensu low-teen revenue growth project
balanc sheet overhang remov augment inject approv in-hand sens
lower extrem turnaround materi stock set-up risk-reward look
increasingli compel us reiter op rate
doubl digit growth teen achiev beyond
believ well posit exit revenue growth profil rang
acceler low-teen territori ceo palmisano
express confid track see lower extremities/upp extrem
busi lower upper market rate exit year move
would suggest back dd sale growth territori least sell day adj
basi matter qtr key compon achiev center around sustain
above-market growth upper extrem segment re-acceler growth back
possibl end-mkt rate lower extrem highlight commentari around
busi market trend
management believ lower extrem segment posit exit
growth rate trend market rate hsd management believ overal lower
extrem end-market growth roughli rang lower extrem end-
market less differenti offer trend closer howev
tar charcot foot grow much faster nearli rate includ
segment overal market closer
management think upper extrem busi sustain mid-teen growth
busi near term guidanc call mid-to-high
teen longer term well even compani begin anniversari
tough y/i comp model upper extrem growth
amid still-healthi hsd end-market management believ market share gain
possibl lower upper extrem segment time given
expect rise rep product new product launch share gain
upper extrem alreadi occur compani upper extrem growth
track well market lower extrem -- -a new product launch gain
traction new reps/territori expans come product curv -- -the compani
strive first toward get back hsd end market growth exit
time hope see share gain drive growth faster pace vs end-mkt
part model organ cc growth ramp growth
growth roughli line consensu
street project ultim came away discuss
management increas confid upward bia estim especi
augment inject approv in-hand achiev above-consensu
lower extrem busi clearli better growth trajectori move
look ahead beyond
view management tone posit turnaround lower extrem
busi meet sens posit momentum seen like
carri lower extrem segment recal earli management hired/
promot new rep ad new territori respons share loss
begun experi within core lower extrem plates/screw prod
categori flash forward year seem sale forc expans effort final
head right direct management note core lower extrem revenue return growth late
qtr mar feb jan better execut matur sale forc rep make step-
wise progress account increas product better meded/train management seem
confid lower extrem busi see sequenti y/i growth improv move
new/ongo product launch augment inject prostep mi salvat
ortholoc pick steam management believ line sight albeit time provid
eventu get rep lower extrem rep product back importantli
improv seen date even includ new product prostep contribut
help drive increas momentum lower extrem busi
management provid increment context/background regard trend
compani share loss certain core segment past year help
us better understand compani deficit how/whi compani
potenti better posit go forward follow trnx merger
end relationship legaci indirect trnx lower extrem distributor favor wmgi
direct lower extrem sale forc ultim creat environ competitor
emerg distributor turn non-wmgi/trnx product
increasingli began partner ambulatori surgeri center custom number
 procedur mostli forefoot midfoot type procedur began migrat
hospit care set procedur tend involv run-of-the-mil plate
screw offer repres less differenti type product
categor refer core amid trend toward asc competitor
better job capit frequent touchpoint even case tailor
product offer focus advanc product sale total ankl
charcot foot higher asp product big growth engin -- -albeit mostli perform
hospit inpati set -- -and admittedli compani well-posit
segment lost ground competit
howev sound though sale forc greater success sell
asc care set surgeri mid forefoot
migrat past year under-perform management
express confid compani increas success target asc
feet street better territori coverag offer procedur price
model vs product line-item price occur hospit understand certain
administr aspect purchas process may less sophist especi
physician-own asc vs place hospit thu find rep
offer custom singl consist price overal procedur cours
negoti accept custom involv product requir perform
given surgeri vs line item line item asc will work management
emphas bundl price current impact compani asp given
wide-rang product differ price point work satisfi
differ custom surgeri need ultim margin product fairli
consist instanc procedur bundle/pr model actual work
wmgi favor procedur asp sometim greater ultim consum
management estim roughli mid/forefoot procedur perform hospit
outpati asc expect rest mid-forefoot market gradual follow
come year
augment inject increment growth momentum driver start
way background augment inject ai bring new form augment bone
graft franchis putti form current novel biolog orthopaed
market address market oppti compani estim altern autograft
use ankl and/or hindfoot fusion procedur augment inject approv
clinic indic augment bone graft classic us approval/commerci enabl
expand augment franchis meet need foot ankl surgeon
augment inject drug-devic combin product consist recombin human
platelet deriv growth factor rhpdgf-bb blend type collagen beta tri-calcium
phosphat provid clinic proven safe effect altern autograft use
hindfoot ankl fusion easy-to-us flowabl formul augment bone graft
augment inject offer benefit pt provid avoid need secondari
surgic site relat harvest autograft tissu result prolong harvest site
pain comorbid patient
management cite sever benefit associ improv handl characterist
augment inject includ enhanc surgeri effici conveni better surfac
coverag ai save minut procedur allow staff prepar syring
reach surgeon well use syring apparatu appli toothpaste-lik
materi joint vs augment classic like wet sand
cumbersom control/deliv syring provid better reach difficult anatomi
better coverag treat area meanwhil augment classic use spoon appli
granular putti joint management highlight area ai help drive growth
exist augment classic user new account physician reluct use
augment classic due less desir handl characterist well management believ ai
could halo effect captur lower extrem hardwar busi believ hardwar
pull-through could repres anoth potenti sourc upsid futur
increment momentum driver wmgi biolog franchis help drive
increas penetr compani estim us market opportun management
specif quantifi ai would impact us augment sale and/or biolog growth
compani highlight intern experi australia canada ai addit
biolog divis whole help fuel growth y/i specif
augment franchis clear us base augment bone graft growth rate
prior ai introduct much acceler truli repres vs
augment bone graft origin whether us ramp faster slower similar vs
play australia/canada and/or time period growth ramp occur
thu entir clear one extrapol datapoint potenti us
estim augment bone graft classic current track us
sale ai like repres upsid bia our/consensu think
build ai sale contribut current revenue forecast think
consensu model either upsid our/consensu us biolog growth
estim lpe y/i management like provid specif segment guidanc
possibl ai contribut issu result assum ai drive
growth lift us augment forecast would repres addtl
revenu growth contribut top current organ sell-day adj cc forecast
growth lift growth project street
total revenu biolog revenue alreadi contempl increment benefit
biolog segment potenti ai sale higher lower extrem rep product
howev think street factor much step-up biolog sale
consensu number like gravit toward possibl even forecast
out-year increas confid low-teen cc revenue growth project
next two year thu rel consensu sale ai contribut
assumpt direct correct roughli doubl would mean
extra growth vs consensu expect current call y/i model
growth us biolog growth estim everi increment
penetr market opportun current us market
penetr forecast potenti repres addt point growth vs annual revenue
addit augment inject prostep anoth product launch
lower extrem platform other
management highlight sever key product launch focu
product launch help drive growth rate line better market rate
exit management indic product featured/launch
upcom american orthopaed foot ankl societi aofa confer boston
includ augment inject launch aofa prostep mi minim invas
surgeri mi platform launch juli salvat nexgen system salvat
line help pick share charcot case -- -launch juli on-going
rollout wmgi ankl fractur small bone fractur system began late
 ankl coat launch set later
prostep mi platform provid import mi product addit portfolio
leverag expand lower extrem sale organ better target
core lower extrem case -- -and view mi angl align particularli well
trend forefoot midfoot surgeri toward hospit outpatient/asc set
system acquir sever year ago sinc refin lead us
launch/re-brand known prostep similar version offer
avail intern primarili uk last sever year brand known
mica system launch us incorpor number instrument technique-
relat improv mica system
initi prostep target forefoot procedur management estim
procedur opportun us annual inclus bunionectomi cheilectomi
key advantag system prostep mi includ less pain
smaller incis shorter oper time week recoveri vs sever month
 cosmesi two pinhol vs long scar involv current bunionectomi treatment
time management expect product see expand util type procedur
mid-foot possibl elsewher extrem anatomi
encouragingli management indic educ sale forc protocol
mede initi prostep sinc begin year sale forc hit
ground run product launch juli physician train standpoint
import procedur adopt curv heavili depend upon success
physician train effort techniqu depend procedur management remain confid
taken appropri step ensur success train partner key thought leader
use product refin surgic techniqu prepar launch
upper extrem blueprint highlight differenti run
management remain confid mid-to-high teen upper extrem growth outlook
highlight blueprint technolog allow compani maintain share gain
prospect year come shoulder segment ceo palmisano believ
move posit ww shoulder segment current move behind op
displac op matter year behind confid compani belief
blueprint pre-plan softwar solut play import role sustain market share
gain especi facilit newer procedur gain traction stemless
shoulder categori on-going use revers shoulder case management offer one anecdot
competit convers account within past week note compani actual convert
higher volum competit surgeon perform shoulder per year result
physician posit experi blueprint stemless revers shoulder case
remind compani charg blueprint part wmgi overal shoulder
offer acquir technolog behind blueprint acquisit
imascap blueprint essenti softwar enabl technolog -- -includ advanc element
artifici intellig augment realiti -- -that help surgeon visual patient shoulder
optim surgic plan custom patient uniqu anatomi
furthermor compani believ stemless shoulder competit
eventu heat us blueprint could make wmgi offer stickier less
suscept competit system trial may appreci far exac
nr receiv us approv respect stemless shoulder offer rel new
categori us year player market
simplic shoulder believ exactech stemless product commerci
launch yet solut commerci said run
much field said ceo palmisano fulli expect stemless shoulder competit
heat next month point even still think categori larg
under-penetrated remain confid sustain lead posit expand
categori part due differenti aspect portfolio blueprint
margin expans remain focu manag
twenti percent ebitda margin goal track management sight set achiev
time management remain confid long-term ebitda margin outlook exit
would higher current margin achiev
remind compani deliv underli ebitda margin expans
inclus benefit lower stock-bas compens bonus werent
trigger last year due sale under-perform margin expans achiev
top-lin growth rate given wmgi top-lin acceler prospect dd territori
management commentari dd top-lin achiev without big increment increas
 expens leverag wmgi margin expans trajectori toward like
appear much intact part model adj ebitda margin
organ sell day adj revenue growth reflect op margin y/i improv
toward upper-end management current guidanc adj ebitda
suggest ebitda margin rang model adj ebitda margin reach
compani exit year ebitda margin would
reflect annual ebitda margin expans period revenue
growth assum dd top-lin growth sustain beyond think ebitda
margin like within next year discuss management said much
express confid ebitda margin achiev sustain dd sale
growth situat assum minim expens growth management goal
compani think room reduc expens keep flat
howev would like requir increment spend near term execut cost reduct
plan compani prioriti acceler profit growth beyond
management guid nonetheless highlight opportun acceler expens
reduct achiev ebitda margin expans beyond rang potenti
near gross margin profil sustain management express confid
compani prospect sustain gm rang close go forward given
favor mix shift dynam busi increas proport sale higher
margin area revers shoulder stemless shoulder total ankl advanc biolog
offer augment model gm increas
respect potenti futur price pressur management acknowledg trend
surgeri lower-cost acss core lower-extrem might eventu lead
downward price pressur time compani see meaning impact
yet mention management remain confid better posit today go
forward negoti procedure-ori contract custom major
impact overal asp improv eas busi asc allow
better penetr account -- -an area struggl get vs smaller
player us sound compani right-siz procedur price vs individu sku
price offer inpatient/outpati set includ hardwar requir
surgeri depend whether goe under/ov hardwar alloc bundl
procedur price make excess profit eat cost provid addit hardwar
 a/bal sheet commentari consist messag call
opportunist pursu tuck-in technolog orient come across
must-hav technolog blueprint need add-on new major
platforms/area cfo berri indic compani immin need new
asset howev compani remain opportunist emerg technolog
blueprint biolog piqu interest could addit compani long-term growth
profil past compani use convert financ deal larg major
compani outstand debt burden today use straight debt smaller size deal
compani reiter comfort current cash posit remind
experienc boost insur settlement cash inflow addtl
capac exist loan agreement sever month ago therebi elimin need
pt increas vs prior feel comfort appli higher vs
prior ev/sal multipl revenue forecast given augment
inject approv think lead upward consensu estim revis recent
posit discuss senior leadership team site visit follow
increas confid achiev above-consensu out-year revenue growth
forecast reflect low-teen growth think multipl still room play
addt catch-up rest small-cap med-tech experienc multipl expans
sinc last valuat updat small-cap med-tech peer
trade ev/sal average revenue growth prospect
perhap slight discount still warrant given high leverag ratio
debt/ebitda view low-teen top-lin growth prospect gm profil
fetch closer an-lin peer group ev/sal multipl vs current discount vs
especi consid end-mkt among best med-tech
let alon ortho grow hsd think least revenue grower exit
acceler potenti toward low-teen
price target could risk key invest turnaround initi prove
difficult take longer expect yield hoped-for result gm improv improv cash
flow higher sale rep product faster extrem growth etc recent rep hire lower
extrem segment yield hope payoff see rise product rate time
fashion trnx dis-synergi wors anticip expect cost synergi
materi time fashion shoulder market experi deceler
growth product liability/litig claim result advers legal outcom relat
compani divest hip/kne busi potenti requir pay larger anticip
cash settlement -- beyond amount alreadi reserv settl
dollar million except per share data
sale
sell gener administr
research develop
amort intang asset
provis benefit incom tax
net income/ loss cont op
weighted-averag number share outstand dilut
compani report leerink partner estim full year estim continu oper ex-larg
dollar million except per share data
y/i growth day cc
leerink partner estim compani report
